Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 15/20 | 0.50 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | ACLY | P53396 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1993598 | 0.89 | PTGDR2 (0.61) | PTGDR2ALOX5APFEN1ACLY | |
| SCHEMBL1994281 | 0.87 | PTGDR2 (0.51) | PTGDR2PKM | |
| SCHEMBL1991023 | 0.87 | PTGDR2 (0.48) | PTGDR2ALOX5APFEN1ACLYPKM | |
| SCHEMBL3388387 | 0.87 | PTGDR2 (0.58) | PTGDR2ALOX5APFEN1ACLY | |
| SCHEMBL1988963 | 0.86 | PTGDR2 (0.60) | PTGDR2 | |
| SCHEMBL1993889 | 0.86 | PTGDR2 (0.54) | PTGDR2ALOX5APFEN1PKMMMP1 | |
| SCHEMBL1989553 | 0.82 | HTR6 (0.51) | ACLY | |
| SCHEMBL1992062 | 0.81 | ABCB11 (0.49) | PTGDR2ALOX5APFEN1PKMMMP1 | |
| SCHEMBL12394550 | 0.80 | PTGDR2 (0.61) | PTGDR2 | |
| SCHEMBL1989784 | 0.80 | PTGDR2 (0.58) | PTGDR2ALOX5APFEN1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415394-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (GB) | 2013-04-09 | — | — | US | claimed |
| US-20120178814-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | LUKER TIMOTHY JON (GB) | 2012-07-12 | — | — | US | claimed |
| US-20110152374-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | US | claimed |
| EP-1937633-B1 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2010-08-04 | — | — | EP | claimed |
| US-20090036535-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | claimed |
| US-8415394-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (GB) | 2013-04-09 | — | — | US | disclosed |
| US-8415394-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (GB) | 2013-04-09 | — | — | US | disclosed |
| US-8415394-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (GB) | 2013-04-09 | — | — | US | disclosed |
| US-8349897-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2013-01-08 | — | — | US | disclosed |
| US-8349897-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2013-01-08 | — | — | US | disclosed |
| US-8349897-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2013-01-08 | — | — | US | disclosed |
| US-20120178814-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | LUKER TIMOTHY JON (GB) | 2012-07-12 | — | — | US | disclosed |
| US-8008350-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2011-08-30 | — | — | US | disclosed |
| US-20110152374-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | US | disclosed |
| US-20110152374-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | US | disclosed |
| US-20110152374-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | US | disclosed |
| EP-1937633-B1 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2010-08-04 | — | — | EP | disclosed |
| US-20090036535-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
| US-20090036535-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
| US-20090036535-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178814-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | BPGM, PPARA, HPD | PTGDR2 568/4885ALOX5AP 701/4885FEN1 4495/4885 |
| US-20110152374-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | BPGM, PPARA, HPD | PTGDR2 568/4885ALOX5AP 701/4885FEN1 4495/4885 |
| US-20090036535-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | BPGM, PPARA, HPD | PTGDR2 568/4885ALOX5AP 701/4885FEN1 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.